Medroxyprogesterone
Active ingredient · 3 therapeutic classes
Sold as CLIMANOR · AA-MEDROXY · DEPO-PROVERA
- Drug class
- Progestogens
- Availability
- Prescription only
- Routes
- Oral, Intramuscular
- Markets covered
- 3
- Products on record
- 65
- FDA reports (12 mo)
- 3,393
Overview
Plain-language summary, compiled from the cited regulatory records
Medroxyprogesterone is a progestin [1]. It belongs to the drug class of progestogens [1].
This medication is approved for use by females of reproductive potential to prevent pregnancy [1]. However, its use is not recommended as a long-term birth control method, generally longer than 2 years, unless other options are considered inadequate [1].
In the past 12 months, there were 3,393 adverse event reports associated with this active ingredient [2]. Among the reported adverse events were meningioma, meningioma benign, off-label use, nausea, and device leakage [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 49 | May 29, 2026 |
| CA Canada | Health Canada | 9 | May 19, 2026 |
| US United States | FDA | 7 | May 27, 2026 |
GBUnited Kingdom· MHRA
49 products
Uses
Progestogen. Indicated for dysfunctional (anovulatory) uterine bleeding, secondary amenorrhoea and for mild to moderate endometriosis.
How to take
CACanada· Health Canada
9 products
Uses
AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for: • Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and significantly reduce the risk of hyperplasia and carcinoma; • Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the absence of organic pathology; • Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial carcinoma; • Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women.
For indications not including breast cancer, AA-MEDROXY should be prescribed only to women with intact uteri. 1 Pediatrics Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
4 Geriatrics.
USUnited States· FDA
7 products
Uses
1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. 1)]. Medroxyprogesterone acetate is a progestin indicated for use by females of reproductive potential to prevent pregnancy.
, longer than 2 years) birth control method unless other options are considered inadequate. 1)
How to take
Drug interactions
Known interactions involving Medroxyprogesterone. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL000571037 · revised April 22, 2025
- [2]Health Canada (DPD) · 02244726 · revised April 1, 2025
- [3]FDA DailyMed · 01e28bef-9758-40… · revised December 14, 2022 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.